North America Sickle Cell Disease Market Trends, Growth, Demand, opportunities, Scope & Forecast period



 Sickle cell disease (SCD) is a series of inherited red blood cell abnormalities in which an individual's red blood cells become sticky and practically "C" or curved in shape, hence the name "sickle cell disease." Sickle cell anemia, sickle cell beta-thalassemia, sickle Hemoglobin C Disease, and other sickle cell disorders are among them. Anemia, periods of discomfort, swelling of the hands and feet, and other symptoms are all connected with sickle cell disease.

gastrointestinal effects such as gastric distress, gastritis, mucositis, and oral mucosa ulcer, dermatological effects such as painful skin ulcers, aphthous ulcers, non-ulcerative toxicity with erythema, and skin infiltration, and it can also decrease sperm count and motility in males are all major side effects of hydroxyurea on long-term treatment in sickle cell disease patients. Medications and blood transfusions are used to treat sickle cell disease. A stem cell transplant may be able to treat the condition in certain children and teenagers.

Over the projected period, the North American sickle cell disease market is expected to rise due to an increase in product approvals by key companies for the treatment of sickle cell disease. For example, in May 2021, Chiesi Farmaceutici S.p.A., a the pharmaceutical company announced that FERRIPROX (deferiprone) had been approved by the US Food and Drug Administration for the treatment of transfusional iron overload due to sickle cell disease (SCD) and anemia in pediatric and adult patients aged three years and older.

The North America sickle cell disease market is projected to be hampered by major adverse effects of pharmacological treatments such as hydroxyurea. According to a report published by Starpearls, an authenticated healthcare library around the world, and articles reviewed by PubMed (MEDLINE database of references and abstracts on life sciences and biomedical topics), hydroxyurea has gastrointestinal, dermatological, and reptilian side effects on long-term treatment in sickle cell disease patients.

Novartis International AG, Bristol-Myers Squibb Company, Bluebird Bio, Global Blood Therapeutics, Inc., Pfizer Inc., Emmaus Life Sciences, Inc., ADDMEDICA, Sangamo Therapeutics, Inc., Acceleron Pharma, Inc., Agios Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals, Inc., and Imara, Inc. are among the major players in the North American

Comments

Popular posts from this blog

Quaternary Ammonium Compounds Market to Grow at USD 1.63 billion by 2027: COVID Impact & Post COVID Analysis, Business Opportunities, and Strategies

Butyraldehyde Market Trends, Growth, Demand, opportunities, Scope & Forecast 2027 by CMI

Glass Mat Thermoplastic Market : Size, Growth, Regional Analysis, And Market Area